540788 ASPIRA

Aspira Pathlab & Diagnostics Share Price

 

 

Start SIP in ASPIRA

Start SIP

Performance

  • Low
  • ₹68
  • High
  • ₹68
  • 52 Week Low
  • ₹50
  • 52 Week High
  • ₹107
  • Open Price₹68
  • Previous Close₹68
  • Volume951
  • 50 DMA₹64.55
  • 100 DMA₹64.22
  • 200 DMA₹63.06

Investment Returns

  • Over 1 Month + 9.38%
  • Over 3 Month + 11.13%
  • Over 6 Month + 8.45%
  • Over 1 Year -0.98%

Smart Investing Starts Here Start SIP with Aspira Pathlab & Diagnostics for Steady Growth!

Invest Now

Aspira Pathlab & Diagnostics Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 20.6
  • PEG Ratio
  • 0
  • Market Cap Cr
  • 70
  • P/B Ratio
  • 4.9
  • Average True Range
  • 3.63
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.18
  • RSI
  • 56.51
  • MFI
  • 72.37

Aspira Pathlab & Diagnostics Financials

Aspira Pathlab & Diagnostics Technicals

EMA & SMA

Current Price
₹68.00
+ 0.01 (0.01%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹64.65
  • 50 Day
  • ₹64.55
  • 100 Day
  • ₹64.22
  • 200 Day
  • ₹63.06

Resistance and Support

68 Pivot Speed
  • R3 68.01
  • R2 68.01
  • R1 68.00
  • S1 67.99
  • S2 67.99
  • S3 67.98

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Aspira Pathlab & Diag has an operating revenue of Rs. 24.52 Cr. on a trailing 12-month basis. An annual revenue growth of 64% is outstanding, Pre-tax margin of 9% is okay, ROE of 27% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 7% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It is currently FORMING a base in its weekly chart and is trading around 12% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 73 which is a FAIR score but needs to improve its earnings, a RS Rating of 76 which is FAIR indicating the recent price performance, Buyer Demand at D+ which indicates heavy supply, Group Rank of 113 indicates it belongs to a poor industry group of Medical-Services and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Aspira Pathlab & Diagnostics Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-10 Quarterly Results
2025-11-12 Quarterly Results
2025-08-12 Quarterly Results
2025-05-16 Audited Results
2025-02-07 Quarterly Results

Aspira Pathlab & Diagnostics F&O

Aspira Pathlab & Diagnostics Shareholding Pattern

18.39%
60.07%
21.54%

About Aspira Pathlab & Diagnostics

  • NSE Symbol
  • ASPIRA
  • BSE Symbol
  • 540788
  • Managing Director & CEO
  • Dr. Pankaj J Shah
  • ISIN
  • INE500C01017

Similar Stocks to Aspira Pathlab & Diagnostics

Aspira Pathlab & Diagnostics FAQs

Aspira Pathlab & Diagnostics share price is ₹68 As on 10 February, 2026 | 22:47

The Market Cap of Aspira Pathlab & Diagnostics is ₹70 Cr As on 10 February, 2026 | 22:47

The P/E ratio of Aspira Pathlab & Diagnostics is 20.6 As on 10 February, 2026 | 22:47

The PB ratio of Aspira Pathlab & Diagnostics is 4.9 As on 10 February, 2026 | 22:47

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23